ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer’s disease, AD. PMN310, a humanized IgG1 antibody, is engineered to selectively target toxic oligomers of amyloid-beta-which are believed to be a key driver of Alzheimer’s pathology-while avoiding interaction with plaque deposits. This mechanism is designed to help reduce the risk of amyloid-related imaging abnormalities, a common side effect associated with existing therapies, potentially offering a differentiated product profile.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN: